Researchers at Oregon Health & Science University reported that combining venetoclax with the CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia activity than venetoclax alone across >300 patient samples and in mouse xenografts, according to a Cell Reports Medicine paper. The combination appears to co‑target cell‑cycle and protein synthesis pathways and overcome common resistance mechanisms. Authors proposed the regimen to address near‑universal resistance to venetoclax‑based therapies in AML and provided mechanistic data supporting further preclinical development and potential clinical trials. The study frames CDK4/6 inhibition as a strategy to extend response durability in a frontline AML setting.